Cysteamine inhibited primary tumors and metastatic lesions in an orthotopic pancreatic cancer <i>in vivo</i>.

<p>HS766T and MIA-PaCa2 cells (2×10⁶) were implanted directly into the pancreas of 5–6 week-old female nude <i>nu/nu</i> mice and then peritoneal cavity and skin were closed using clips. Increasing doses of cysteamine were injected s.c. as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0034437#s2" target="_blank">materials and methods</a>. Primary tumors and metastatic lesions of ≥ 5 mm were counted in vehicle and cysteamine treated mice. <i>a</i>: P<0.05, <i>b</i>: P<0.01 and <i>c</i>: P<0.05, <i>d:</i> P<0.001. +: moderate ascites, ++: severe ascites, –: no ascites.